Article
Acute intermittent porphyria: A single-base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide
Article first published online: 16 MAY 2005
DOI: 10.1002/ajmg.1320580213
Copyright © 1995 Wiley-Liss, Inc., A Wiley Company
Additional Information
How to Cite
Lee, G. Y., Astrin, K. H. and Desnick, R. J. (1995), Acute intermittent porphyria: A single-base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide. Am. J. Med. Genet., 58: 155–158. doi: 10.1002/ajmg.1320580213
Publication History
- Issue published online: 16 MAY 2005
- Article first published online: 16 MAY 2005
- Manuscript Revised: 16 FEB 1995
- Manuscript Received: 28 OCT 1994
- Abstract
- References
- Cited By
Keywords:
- acute intermittent porphyria;
- hydroxymethylbilane synthase;
- porphobilinogen;
- molecular diagnosis
Abstract
Acute intermittent porphyria (AIP) is an autosomal-dominant inborn error of metabolism that results from the half-normal activity of the third enzyme in the heme biosynthetic pathway, hydroxymethylbilane synthase (HMB-synthase). AIP is an ecogenetic condition, since the life-threatening acute attacks are precipitated by various factors, including drugs, alcohol, fasting, and certain hormones. Biochemical diagnosis is problematic, and the identification of mutations in the HMB-synthase gene provides accurate detection of presymptomatic heterozygotes, permitting avoidance of the acute precipitating factors. By direct solidphase sequencing, two mutations causing AIP were identified, an adenine deletion at position 629 in exon 11(629delA), which alters the reading frame and predicts premature truncation of the enzyme protein after amino acid 255, and a nonsense mutation in exon 12 (R225X). These mutations were confirmed by either restriction enzyme analysis or family studies of symptomatic patients, permitting accurate presymptomatic diagnosis of affected relatives. © 1995 Wiley-Liss, Inc.

1552-4833/asset/olbannerleft.gif?v=1&s=dc5513758e0602016bfe88cd52afd78bf862aab9)
1552-4833/asset/olbannerright.gif?v=1&s=c3d8a0f0a45667625907578ec1e0f011cbe060b1)
1552-4833/asset/cover.gif?v=1&s=9818ec8c89d0772bf0e752b15694c460afb83f9f)